Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin… (NCT06805994) | Clinical Trial Compass
RecruitingPhase 1
Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment
United States175 participantsStarted 2025-08-27
Plain-language summary
This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
Who can participate
Age range0 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Child has had a prior nasal surveillance culture grow S. aurues
✓. Child is \<18 years of age
✓. Child completed treatment with intranasal mupirocin for S. aureus nasal colonization as part of routine clinical care two or more days before the planned transplant
✓. Child has anticipated hospital length of stay \>3 days after completing intranasal mupirocin treatment
✓. Infant \>25 weeks gestation unless \>2 months chronological age
Exclusion criteria
✕. Child is a ward of the State
✕. Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)
✕. Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)
✕. Donor is able to provide informed consent
✕. Donor has a relationship with the child outside of the hospital setting (i.e., not an ICU caregiver)
✕. Donor had positive COVID-19 test in prior 21 days
✕. Donor with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough)
✕
What they're measuring
1
Pediatric nasal microbiome diversity after parent-to-child NMT.
Timeframe: Day 2, 4, 7, 10, 14 days post-intervention